Force 3 Medical Named VerifyNow Canadian Distributor
Accumetrics, Inc., developer of the VerifyNow® System, the
first rapid and easy-to-use system for measuring platelet reactivity to
multiple antiplatelet agents, announced today that the VerifyNow System
has been licensed for clinical use by Health Canada. The VerifyNow
System is now available to hospitals and clinical laboratories in Canada
to measure platelet reactivity in patients on antiplatelet medications
including aspirin and P2Y12 inhibitors (clopidogrel).
Additionally, Accumetrics has signed an agreement with Force 3 Medical,
Inc. for distribution of the VerifyNow System in Canada. With the
addition of Force 3 Medical to Accumetrics’ growing number of
distribution partners, Accumetrics now has local representation in over
70 countries worldwide.
“Achieving a Health Canada license is another important milestone in our
mission to provide patients and healthcare professionals the highest
quality clinical evidence that allows for improved management of
cardiovascular disease throughout the world,” said Timothy I. Still,
President and CEO of Accumetrics, Inc. “With Force 3 Medical as our
Canadian distribution partner, we are very confident that the VerifyNow
offering will quickly achieve a strong presence in this important
“The VerifyNow System is being used in the PROACT (Prospective
Randomized ON-X Valve Anticoagulation Clinical Trial) study, and the
four Canadian contributing centers have been impressed with its
usefulness in managing patients’ antiplatelet treatment strategies,”
said Gilbert Pommepuy, President and CEO of Force 3 Medical, Inc. “We
are very excited at the prospect of being able to expand the use of the
VerifyNow System and making it a new standard of care.”
About Accumetrics (www.accumetrics.com)
Accumetrics is committed to advancing medical understanding of platelet
function and enhancing quality of care for patients receiving
antiplatelet therapies by providing industry-leading and widely
accessible diagnostic tests for rapid platelet function assessment.
Accumetrics’ VerifyNow System is the first rapid and easy-to-use
platform to help physicians determine an individual’s response to
multiple antiplatelet agents. Addressing every major antiplatelet drug,
including FDA-cleared products for aspirin and P2Y12 inhibitors (e.g.
clopidogrel), the VerifyNow System provides valuable information to help
physicians make informed clinical decisions. The VerifyNow P2Y12 Test is
a whole blood assay used to measure the level of platelet P2Y12 receptor
blockade. Additionally, it is indicated outside the US and Canada for
evaluating the risk for recurrent events in cardiovascular patients. The
VerifyNow System is used by physicians in over 800 facilities in the
United States and over 70 countries worldwide where antiplatelet
medications are prescribed to reduce the occurrence of future thrombotic
events such as heart attack and stroke. For more information about the
Company and its products, visit www.accumetrics.com.
The Accumetrics logo and VerifyNow are registered trademarks of
About Force 3 Medical, Inc.
Force 3 Medical, Inc. is a Canadian company distributing medical devices
and equipment designed for cardiovascular physicians. With 29 years of
experience in successfully launching new technologies to the Canadian
cardiovascular/interventional cardiology market, the company specializes
in the distribution and launch of innovative medical technology.